SPONSORED:

Key House Dem: I don't want to 'punish' drug companies

Key House Dem: I don't want to 'punish' drug companies
© Greg Nash

A key Democrat on drug pricing issues said Wednesday that she does not want to “punish” the pharmaceutical industry, striking a softer tone than many other Democrats do on the issue.

Rep. Anna EshooAnna Georges EshooHow to expand rural broadband, fast and affordably Hillicon Valley: Productivity, fatigue, cybersecurity emerge as top concerns amid pandemic | Facebook critics launch alternative oversight board | Google to temporarily bar election ads after polls close Lawmakers introduce legislation to boost cybersecurity of local governments, small businesses MORE (D-Calif.), the new chairwoman of the powerful Energy and Commerce health subcommittee, has received criticism from some drug pricing advocates that she is too close to the pharmaceutical industry.  

Asked about the criticism on Wednesday and if she would be tough on drug companies, Eshoo told reporters, “I'm going to be fair. I'm not out to punish or to do things out of vengeance.”

ADVERTISEMENT

“I want the best policy that we can come up with that's really terrific for the American people; that’s my goal,” she added.

While some other House Democrats are pushing for sweeping legislation to attack drug prices, such as allowing Medicare to negotiate prices, Eshoo is treading more carefully.  

Asked if she wanted to move legislation to address drug prices, Eshoo said, “I think we need to examine it first.”

“How do we know what the answer to something is if we don't see the entirety of the issue that you want to do something about,” she continued.

Meanwhile, other Democrats are pushing stronger action. Reps. Elijah CummingsElijah Eugene Cummings'Kamala' and 'Kobe' surge in popularity among baby names Women of color flex political might Black GOP candidate accuses Behar of wearing black face in heated interview MORE (D-Md.), Peter WelchPeter Francis WelchDemocrats to determine leaders after disappointing election Shakespeare Theatre Company goes virtual for 'Will on the Hill...or Won't They?' Vermont Rep. Peter Welch easily wins primary MORE (D-Vt.), and others joined Sen. Bernie SandersBernie SandersThe Memo: Biden faces tough road on pledge to heal nation Clyburn: Biden falling short on naming Black figures to top posts Prepare for buyers' remorse when Biden/Harris nationalize health care MORE (I-Vt.) last week to unveil three sweeping bills, including a bill to strip monopolies from drug companies if their prices are above the average price in other wealthy countries.

A leading drug pricing advocacy group, Patients for Affordable Drugs Now, ran ads against Eshoo last year, saying she was “in the pocket of Big Pharma.”

Ben Wakana, the group’s executive director, pushed back on Eshoo’s call on Wednesday to “examine” the issue before acting.

“We don’t need more hearings to study the problem,” Wakana wrote in an email. “We need to advance legislation that the American people overwhelmingly support and Congress was elected to deliver: Reforms to fix a rigged system, break the monopoly pricing power of drug corporations and protect Americans from Big Pharma’s price gouging.”